Adagene, City of Hope launch Phase 1 trial of colorectal cancer combination therapy
ADAG•Adagene and City of Hope launched a Phase 1 trial of ivonescimab with muzastotug (ADG126) for advanced microsatellite-stable colorectal cancer, with enrollment of up to 36 patients whose cancer progressed on prior systemic therapy.
1. Trial begins
The Phase 1 study will evaluate safety and preliminary antitumor activity to identify an optimal dose. Later stages will add chemotherapy to explore the combination as maintenance therapy and an earlier treatment option; its benefits remain to be established.




